Brief: Sangamo Therapeutics Announces Global Epigenetic Regulation And Capsid Delivery License Agreement With Genentech

Sangamo Therapeutics

06/08/2024 13:09

Aug 6 (Reuters) - Sangamo Therapeutics Inc  SGMO.O :
    * SANGAMO THERAPEUTICS ANNOUNCES GLOBAL EPIGENETIC
REGULATION AND
CAPSID DELIVERY LICENSE AGREEMENT WITH GENENTECH TO DEVELOP
NOVEL GENOMIC MEDICINES FOR NEURODEGENERATIVE DISEASES
    * SANGAMO THERAPEUTICS : ELIGIBLE TO EARN UP TO $1.9 BILLION
IN
MILESTONE PAYMENTS ACROSS MULTIPLE MEDICINES
    * SANGAMO THERAPEUTICS - SEES TO RECEIVE $50 MILLION IN
NEAR-TERM
UPFRONT LICENSE FEES, MILESTONE PAYMENTS AND IS ELIGIBLE TO EARN
UP TO $1.9 BILLION IN DEVELOPMENT MILESTONE PAYMENTS

Source text for Eikon:  ID:nBwb5hNmba 
Further company coverage:  SGMO.O 

 ((Reuters.Briefs@thomsonreuters.com;))